Anju has been a journalist since 1993 including stints at India's leading financial dailies. She covers a range of topics across the pharma and biosimilar landscape. Drug pricing, policy and regulatory affairs, M&A and patents are areas of special interest to her. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Latest from Anju Ghangurde
Huge opportunities for OTC therapies loom in India, as consumerization brings structural reset in healthcare. Success stories on Rx-to-OTC transition augur well for pharma, but a predictable regulatory roadmap will be pivotal for sustainable growth.
Huge opportunities for OTC therapies loom in India, as consumerization brings structural reset in healthcare, as per a new report by EY-Parthenon. Success stories on Rx-to-OTC transition augur well for pharma, but a predictable regulatory roadmap will be pivotal for sustainable growth.
Dr Reddy’s gears for semaglutide debut across markets, including India and Canada, where Novo Nordisk has second brands of the GLP-1 agonist potentially ready. Can the Indian group close out compliance queries from the Canadian regulator soon?
From a biofoundry network and pharma industry backed AI research organization to a small-molecule repurposed drug in Duchenne’s muscular dystrophy, experts discuss a number of advances underway as India seeks to move up the innovation ladder.
Lanreotide supply issues cloud Cipla’s Q3 FY26 earnings, with impact seen in Q4 as well, though pipeline assets augur well for US growth continuity. Perpetual rights to Novartis’s Galvus effective Jan 1, seen adding momentum to India diabetes gains.
Lanreotide supply issues cloud Cipla’s Q3 FY26 earnings, with impact seen in Q4 as well, though pipeline assets augur well for US growth continuity. Perpetual rights to Novartis’s Galvus effective Jan 1, seen adding momentum to India diabetes gains.